Highlights from ASCO 2024: Advancements in Gynecologic Cancer Treatments

Immunotherapy combinations show promising results in clear cell ovarian cancer, while chemotherapy after chemoradiation does not improve outcomes in locally advanced cervical cancer. Novel TIGIT inhibitor plus pembrolizumab combination demonstrates potential for mismatch repair-deficient endometrial cancer.